- Home
- IMXI vs CAPR Comparison
IMXI vs CAPR Comparison
Compare IMXI & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMXI
- CAPR
- Stock Information
- Founded
- IMXI 1994
- CAPR 2005
- Country
- IMXI United States
- CAPR United States
- Employees
- IMXI N/A
- CAPR N/A
- Industry
- IMXI Retail: Computer Software & Peripheral Equipment
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMXI Technology
- CAPR Health Care
- Exchange
- IMXI Nasdaq
- CAPR Nasdaq
- Market Cap
- IMXI 559.5M
- CAPR 622.9M
- IPO Year
- IMXI N/A
- CAPR N/A
- Fundamental
- Price
- IMXI $12.96
- CAPR $12.79
- Analyst Decision
- IMXI Buy
- CAPR Strong Buy
- Analyst Count
- IMXI 7
- CAPR 7
- Target Price
- IMXI $24.40
- CAPR $39.29
- AVG Volume (30 Days)
- IMXI 446.1K
- CAPR 1.5M
- Earning Date
- IMXI 05-07-2025
- CAPR 03-19-2025
- Dividend Yield
- IMXI N/A
- CAPR N/A
- EPS Growth
- IMXI 9.82
- CAPR N/A
- EPS
- IMXI 1.79
- CAPR N/A
- Revenue
- IMXI $658,649,000.00
- CAPR $23,228,045.00
- Revenue This Year
- IMXI $2.72
- CAPR N/A
- Revenue Next Year
- IMXI $3.84
- CAPR $74.85
- P/E Ratio
- IMXI $7.25
- CAPR N/A
- Revenue Growth
- IMXI N/A
- CAPR 65.33
- 52 Week Low
- IMXI $12.82
- CAPR $3.52
- 52 Week High
- IMXI $23.28
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- IMXI 17.94
- CAPR 42.76
- Support Level
- IMXI $12.82
- CAPR $11.75
- Resistance Level
- IMXI $15.98
- CAPR $16.17
- Average True Range (ATR)
- IMXI 0.64
- CAPR 1.51
- MACD
- IMXI -0.23
- CAPR -0.18
- Stochastic Oscillator
- IMXI 2.48
- CAPR 22.96
About IMXI International Money Express Inc.
International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.